Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Local Therapy Clear all
Completed Not applicable Interventional Results available

A Trial Assessing The Association Between Type Of Local Anesthesia Treatment And Postoperative Pain In Patients In Having Undergone Arrhythmia Surgery

NCT01300377
View directory record Official record
Conditions
Post-operative Pain
Interventions
Bupivacaine / Lidocaine, Lidocaine
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Active, not recruiting Phase 3 Interventional

Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

NCT02181257
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Interventions
Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
Combination Product · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Rehabilitation Team Functioning and Patient Outcomes

NCT00237757
View directory record Official record
Conditions
Stroke
Interventions
Information feedback
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 3, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

NCT03352765
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bendamustine, melphalan, Autologous Stem Cell Transplantation (ASCT)
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional

Mitigating the Impact of Stigma and Shame Among People Living With HIV and Substance Use Disorders

NCT05934305
View directory record Official record
Conditions
Hiv, Substance Use Disorders
Interventions
Matter Intervention, Control Condition
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Miami, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention

NCT06852170
View directory record Official record
Conditions
Substance Abuse, Decision Making, Shared, Implementation Science, Decision Making, Organizations, Substance-related Disorders, Policy
Interventions
Co-Design Sessions (CDS), Data products
Other
Lead sponsor
Chestnut Health Systems
Other
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Completed No phase listed Observational

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

NCT03529045
View directory record Official record
Conditions
Epilepsy, Seizures, Drug Resistant Epilepsy
Interventions
Vagus Nerve Stimulation (VNS) Therapy
Device
Lead sponsor
LivaNova
Industry
Eligibility
Not listed
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
19
States / cities
Grand Junction, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy

NCT01032772
View directory record Official record
Conditions
Alcohol Use, Smoking, Contraception
Interventions
Choices Plus, Information
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
2
States / cities
Houston, Texas • Pasadena, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer

NCT00851877
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Cetuximab, Cisplatin, Nab-Paclitaxel, intensity-modulated radiation therapy
Biological · Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

Aerobic Exercise in Parkinson's Disease

NCT03808675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Aerobic walking, Usual care with PD specific health education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Not applicable Interventional Results available

A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall

NCT01819831
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
proton radiation, surgery (wide local excision; limb preservation surgery)
Radiation · Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 98 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting No phase listed Observational

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

NCT05640102
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Zanubrutinib
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Huntsville, Alabama • Mobile, Alabama • Duarte, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Terminated No phase listed Observational

Post-Market Observation Study of Intra-renal Drug Delivery (PROVIDE)

NCT01064895
View directory record Official record
Conditions
Acute Kidney Injury, Acute Renal Failure, Renal Failure Chronic Contrast Induced, Chronic Kidney Disease
Interventions
Benephit catheter for Targeted Renal Therapy
Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Miami, Florida • Miramar, Florida • Blackfoot, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 3, 2026, 5:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

NCT03850535
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 3, 2026, 5:21 AM EDT
Withdrawn No phase listed Observational

Molecular Markers and Genetic Markers in Patients Undergoing Radiation Therapy for Cancer

NCT00899808
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19

NCT04434131
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent Plasma
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 3, 2026, 5:21 AM EDT
Suspended Phase 1 Interventional

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

NCT04266730
View directory record Official record
Conditions
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
PANDA-VAC, Pembrolizumab
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting Not applicable Interventional

Computer Guided Microwave Liver Ablation

NCT07226869
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC)
Interventions
Computer-Assisted Microwave Liver Ablation
Device
Lead sponsor
NE Scientific INC
Industry
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 3, 2026, 5:21 AM EDT
Completed Not applicable Interventional

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors

NCT02528383
View directory record Official record
Conditions
Breast Cancer
Interventions
Vagifem
Behavioral
Lead sponsor
Susan Tannenbaum
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting Phase 3 Interventional

SAfety of Regional Citrate Anticoagulation (SARCA Study)

NCT05339139
View directory record Official record
Conditions
Acute Kidney Injury, ESRD
Interventions
Dialysis
Combination Product
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Orlando, Florida • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 3, 2026, 5:21 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

NCT07048457
View directory record Official record
Conditions
Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Interventions
Radical cystectomy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Active, not recruiting Phase 1 Interventional

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

NCT04505267
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 5:21 AM EDT
Terminated Phase 3 Interventional Results available

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

NCT01132547
View directory record Official record
Conditions
Cancer
Interventions
cyproheptadine hydrochloride, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
2 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
Long Beach, California • Hartford, Connecticut • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Sep 3, 2026, 5:21 AM EDT